NeuroQuiet Reviews (Complaints & Side Effects): Buyers Reveal Unexpected Truths Behind Its Real Effectiveness & Safety
VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) -- NeuroQuiet Reviews In a…
Dupixent (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36…
China Unicom, YunHuan Technology and ZTE win the GSMA GLOMO “Best Mobile Innovation for Cities” award
BARCELONA, Spain, March 6, 2025 /PRNewswire/ -- ZTE Corporation (0763.HK / 000063.SZ),…
RYAM Announces Impressive Fourth Quarter and Full Year 2024 Results and Provides 2025 Guidance
Net sales for 2024 of $1,630 million, down $13 million from the…
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025 12:45 ET | Source: Celldex Therapeutics, Inc. - Greatly…
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need…
DuelNow Launches $DNOW Token Delivering Membership Rewards for Users
LISBON, Portugal, Feb. 7, 2025 /PRNewswire/ -- DuelNow – the trailblazing sports prediction…
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atr
January 22, 2025 17:00 ET | Source: Anthos Therapeutics Secondary endpoints also…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…
Paris 2024 Report Confirms over 50% Carbon Emissions Reduction
20 December 2024 - The Olympic and Paralympic Games Paris 2024 achieved an unprecedented 54.6%…
